Alternatives to TRT: Enclomiphene, hCG, lifestyle, and fertility-preserving options

The main alternatives to TRT are Enclomiphene for secondary or functional hypogonadism when LH is below 8 mIU/mL, hCG at 1,000 to 2,000 IU three times weekly with FSH when fertility is the immediate goal, and structured lifestyle treatment for reversible causes. These options matter because testosterone replacement suppresses gonadotropins and can reduce sperm production. The right choice depends on whether a man has an intact brain to testes signaling pathway, not just on whether his testosterone number is low.

Key takeaways

• TRT suppresses LH and FSH and can markedly lower sperm production, so it is contraindicated in hypogonadal men seeking fertility treatment.^[2]
• Enclomiphene is the first line alternative to TRT for secondary or functional hypogonadism when LH is below 8 mIU/mL because it stimulates the body’s own testosterone production while preserving testicular function.
• hCG is typically dosed at 1,000 to 2,000 IU three times weekly, and FSH at 75 to 150 IU three times weekly when spermatogenesis is the immediate goal.^[5]
• Low calorie diet and physical activity can improve obesity related secondary hypogonadism, but average testosterone gains are modest, about 1 to 2 nmol/L, and testosterone added to structured lifestyle care outperformed placebo plus the same program in the two year T4DM trial.^{[7] [8]}
• At Veedma, men are classified before treatment with symptoms plus morning total testosterone, directly measured free testosterone, LH, and FSH, because Enclomiphene only works when the signaling axis is intact.

Why alternatives matter before starting TRT

TRT can be an effective therapy for documented hypogonadism, but it suppresses LH and FSH and can therefore suppress spermatogenesis, which is why it is the wrong starting point for a man who still wants fertility.^{[2] [5]}

Gonadotropins are the pituitary hormones LH and FSH that tell the testes to make testosterone and sperm.

The clinical mistake is assuming every man with low testosterone needs replacement. Male hypogonadism is a syndrome that requires persistent symptoms plus biochemical evidence, and the next step is classification. High LH with low testosterone points to primary hypogonadism, where the testes are failing and stimulation therapy will not work. Low or normal LH with low testosterone points to secondary or functional hypogonadism, where the testes may still respond and alternatives to TRT become highly relevant. For the fuller distinction, see Primary vs secondary hypogonadism and The complete low testosterone testing guide.^[1]

At Veedma, treatment selection starts with morning testing from 07:00 to 11:00, symptoms, and a panel that includes total testosterone, free testosterone measured directly by equilibrium dialysis with LC-MS/MS, estradiol, LH, FSH, CBC, comprehensive metabolic panel, lipid panel, and PSA when age appropriate. Our working decision thresholds are total testosterone below 350 ng/dL or free testosterone below 100 pg/mL when symptoms persist. Men who already have outside testing, including Function Health panels, can have those results reviewed before repeating labs. This matters because a man with secondary or functional disease may be a candidate for Enclomiphene, while a man with primary disease may need testosterone cypionate or another TRT regimen instead.

When Enclomiphene is the best alternative to TRT

Enclomiphene is the preferred oral alternative to TRT for men with secondary or functional hypogonadism whose LH is below 8 mIU/mL and whose signaling pathway is still intact.^[3]

The HPG axis is the signaling loop between the hypothalamus, pituitary, and testes.

Enclomiphene for low testosterone works by blocking estrogen receptors at the hypothalamus. That changes the brain’s feedback signal, increases GnRH output, and then raises LH and FSH from the pituitary. The testes are then asked to produce testosterone naturally. In randomized phase II trial data, Enclomiphene increased testosterone while sperm counts were maintained, a very different result from topical testosterone, which predictably suppresses sperm production.^[3]

The clinical advantages over TRT follow directly from that mechanism. Because the testes keep working, Enclomiphene preserves spermatogenesis and tends to maintain testicular size and function. Because testosterone rises through endogenous regulation rather than through external dosing peaks, hematocrit pressure is generally lower than with injectable replacement. Because the axis stays active, Enclomiphene may be discontinuable if the underlying drivers of functional hypogonadism are corrected. That makes it especially relevant for younger men, men unsure about future fatherhood, and men with obesity or metabolic disease whose suppression may still be reversible.

Why fertility is preserved

Fertility is preserved because Enclomiphene raises testosterone without turning off LH and FSH. In plain terms, it supports the body’s own production rather than replacing it. That is the core reason it is now central to fertility preserving testosterone treatment in secondary and functional hypogonadism.

Who is and is not a candidate

Enclomiphene is not appropriate in primary hypogonadism, where LH is already high and the testes cannot respond, or in organic pituitary damage, where the signaling problem is structural. It is available in the United States through compounding pharmacies and specialized men’s health clinics, including Veedma, where it is used as a first line option when labs and symptoms support secondary or functional disease. Veedma also provides ongoing monitoring and protocol adjustment, typically with more than 40 biomarkers checked twice yearly, so a man can see whether endogenous production is actually recovering before lifelong replacement is considered.

Enclomiphene and older mixed SERM formulations

Enclomiphene is the oral SERM based option most directly aimed at raising endogenous testosterone while keeping the axis active. Older mixed SERM formulations have also been used in men, but Enclomiphene is the isolated trans isomer and is intended to deliver the testosterone raising effect more selectively.^[3]

A SERM is a selective estrogen receptor modulator, a drug class that changes estrogen signaling in a tissue specific way.

Men searching for an oral fertility preserving alternative to TRT are usually looking for SERM based stimulation therapy, but the clinically cleaner option is Enclomiphene rather than an older mixed formulation. The key clinical point is mechanism: endogenous stimulation tends to preserve testicular function and usually places less pressure on hematocrit than injected testosterone. A 2017 multi institutional Journal of Urology study found lower rates of secondary polycythemia with SERM based stimulation than with testosterone replacement, which aligns with the broader expectation of lower hematocrit risk when testosterone rises endogenously rather than being injected.^[4]

Other SERMs have been studied in men, but they are less specifically supported for male hypogonadism. In current practice, all SERMs remain off label treatments in this setting, and men should still be counseled about class based concerns such as venous thromboembolism risk. In U.S. men’s health practice, Enclomiphene is generally the preferred SERM because it is more selective, better aligned with male physiology, and supported by growing clinical evidence.

Where hCG and FSH fit in fertility preserving testosterone treatment

hCG can stimulate the testes directly, but when fertility and sperm output are the immediate goals, hCG plus FSH is the preferred gonadotropin regimen rather than hCG alone.^[5]

hCG acts like LH at the testis. FSH stimulates the Sertoli cells that support sperm development.

When hCG is used by itself in selected cases

For selected men with secondary hypogonadism whose main goal is restoring testosterone while avoiding TRT, rather than optimizing sperm production in the near term, hCG alone can be a reasonable option because it directly stimulates intratesticular testosterone production. Common dosing is 1,000 to 2,000 IU three times weekly. According to fertility focused clinical reviews, this is most useful when the testes are intact and the main problem is inadequate central signaling rather than testicular failure. Both extractive and recombinant formulations are available and have broadly comparable clinical effects.^[5]

When FSH should be added

FSH is added at 75 to 150 IU three times weekly when spermatogenesis is the actual endpoint, not just serum testosterone. That distinction matters. A man may feel better with restored testosterone on hCG alone yet still need FSH support to optimize sperm production. In practice, hCG plus FSH is therefore the preferred fertility preserving testosterone treatment when conception is the near term goal. If immediate fertility preservation is not required, Enclomiphene is often the preferred alternative because it is oral, preserves the full axis, and avoids a high injection burden.

Where aromatase inhibitors fit and why evidence is limited

Aromatase inhibitors can raise testosterone by lowering estradiol, but they are a niche option rather than a routine substitute for TRT.^[6]

Aromatase is the enzyme that converts testosterone into estradiol, especially in adipose tissue.

Letrozole, anastrozole, and exemestane reduce that conversion and can therefore increase LH driven testosterone output when the HPG axis is intact. This makes theoretical sense in obesity and metabolic disorders, where excess adipose tissue increases aromatase activity and pushes more testosterone toward estradiol. According to a 2011 review in Reproductive Biology and Endocrinology, the main problem is not mechanism, but evidence quality. Long term data are limited, and prolonged estradiol suppression can reduce bone density and increase osteoporosis risk.^[6]

Why lifestyle is first line, and why combination care often works better

Lifestyle treatment is the first step in functional hypogonadism because obesity, medication burden, and metabolic disease can suppress testosterone without permanently damaging the axis.^{[7] [8]}

Functional hypogonadism means the testes and pituitary can still work, but their signaling is being held down by reversible conditions.

A 2013 European Journal of Endocrinology meta analysis found that body weight loss can revert obesity associated secondary hypogonadotropic hypogonadism. Physical activity also improves testosterone, and the improvement correlates with exercise duration and the amount of weight lost. That is the evidence based version of natural testosterone treatment. It means restoring a man’s own production by removing suppressive factors, not buying a commercial booster. The limitation is practical. Average testosterone gains are usually modest, often around 1 to 2 nmol/L, and long term maintenance is difficult.^[7]

The combination approach exists because symptoms themselves can make lifestyle change harder. The two year T4DM trial showed that testosterone added to a structured lifestyle program outperformed placebo plus the same program. In clinical practice, that same logic supports Enclomiphene plus lifestyle as the ideal first line strategy for functional hypogonadism. It addresses root causes while still raising testosterone through the native pathway, preserving fertility and keeping future options open. For more on reversibility, see Functional vs organic hypogonadism.^[8]

Treat the cause when the cause is reversible

When a reversible cause is found, treating that cause may restore testosterone more effectively than immediately starting hormone replacement.^[9]

Pituitary and prolactin causes

Prolactinomas can suppress GnRH and secondarily suppress testosterone, and dopamine agonists can normalize prolactin and restore testosterone in many men. According to Endocrine Reviews, this is one of the clearest examples of why diagnostic workup should come before replacement. Hyperprolactinemia from medications also belongs in this category, because switching the offending drug may remove the hormonal block without committing the patient to TRT.^[9]

Iron overload and drug induced suppression

Iron overload can impair pituitary function, so phlebotomy may improve endocrine function in the right patient. Drug induced hypogonadism should also be handled at the source when possible. Opioids can suppress gonadotropin release. Exogenous testosterone or anabolic steroids suppress the axis through negative feedback. Finasteride can complicate androgen signaling and sexual symptoms. When those agents can be reduced, stopped, or switched, that should happen before lifelong replacement is assumed. If symptoms and low testosterone persist after the cause is addressed, the man should then be reclassified with LH and FSH to determine whether Enclomiphene, gonadotropins, or TRT is the appropriate next step.

What supplements can and cannot do

Correcting a true zinc, vitamin D, or magnesium deficiency can modestly improve testosterone, but over the counter testosterone boosters do not treat clinical hypogonadism.^{[10] [12]}

Deficiency correction means restoring a nutrient that is genuinely low, not adding more of a nutrient that is already adequate.

That distinction matters. Vitamin D, zinc, and magnesium can all matter to endocrine function, but the effect is usually modest and most visible in deficient men. Small human studies of ashwagandha, tongkat ali, and fenugreek suggest possible minor improvements in some settings, but the evidence is limited, short term, and heterogeneous. A 2020 World Journal of Men’s Health review found that many online testosterone boosters rely on ingredients with weak or indirect evidence, despite aggressive marketing.^[10]

Myth vs fact

Myth: TRT is the best first step for any man with low T

Fact: TRT is not the best first step when fertility matters, because it suppresses LH, FSH, and spermatogenesis. Men who may want children should know this before the first prescription is written.^[2]

Myth: Enclomiphene works for every type of hypogonadism

Fact: Enclomiphene works only when the signaling pathway is intact. It is appropriate for secondary and functional hypogonadism, not for primary testicular failure or structural pituitary damage.^[3]

Myth: Lifestyle change alone usually fixes functional hypogonadism

Fact: Weight loss and exercise can help, but the average rise in testosterone is modest, and combination treatment outperformed placebo plus the same lifestyle program in T4DM. For many men, lifestyle is necessary but not sufficient.^{[7] [8]}

Myth: Testosterone boosters are a medical alternative to treatment

Fact: Correcting a real nutrient deficiency may help somewhat, but commercial boosters are largely unproven and do not replace evidence based care for clinical hypogonadism.^[10]

Bottom line

The real alternatives to TRT are Enclomiphene for secondary or functional hypogonadism, hCG with FSH when immediate fertility is the priority, treatment of reversible causes such as prolactin excess or medication related suppression, and lifestyle based recovery for functional disease. The right option depends on symptoms plus morning total and free testosterone, LH, and FSH, because a low number alone does not tell you whether natural production can still be restored. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility. World journal of men’s health. 2019;37:45-54. DOI: 10.5534/wjmh.180036
3. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. BJU International. 2014.
4. Wheeler KM, Smith RP, Kumar RA, et al. A Comparison of Secondary Polycythemia in Hypogonadal Men Treated with Clomiphene Citrate versus Testosterone Replacement: A Multi-Institutional Study. The Journal of urology. 2017;197:1127-1131. PMID: 27984109
5. Kim ED, Crosnoe L, Bar-Chama N, et al. The treatment of hypogonadism in men of reproductive age. Fertility and sterility. 2013;99:718-24. PMID: 23219010
6. de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reproductive biology and endocrinology : RB&E. 2011;9:93. PMID: 21693046
7. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European journal of endocrinology. 2013;168:829-43. PMID: 23482592
8. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. The Lancet Diabetes & Endocrinology. 2021;9:32-45. PMID: 33281059
9. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocrine reviews. 2006;27:485-534. PMID: 16705142
10. Clemesha CG, Thaker H, Samplaski MK. “Testosterone Boosting” Supplements Composition and Claims Are not Supported by the Academic Literature. World journal of men’s health. 2020;38:115-122. PMID: 32081788
11. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England journal of medicine. 2023;389:107-117. PMID: 37326322
12. Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2011;43:223-5. PMID: 21154195